ArticleBiology direct2026
Exosomes from tumor-associated macrophages promote glycolysis and malignant NSCLC progression by delivery of hsa_circ_0000896.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) is amongst the most common tumors, which is responsible for most cancer-related mortality worldwide. Tumor-associated macrophages (TAMs) can regulate tumor microenvironment (TME) and malignant progression of NSCLC; however, the regulatory mechanisms of TAMs exosome (M2-Exo) in the context of NSCLC progression are still unclear. In this study, exosomes isolated from TAMs (M2-Exo) were subjected to FISH and RT-qPCR to explore hsa_circ_0000896 expressions in NSCLC specimens. Dual-luciferase reporter data were utilized to investigate hsa_circ_0000896 downstream targets. Transwell migration, 5-ethynyl-2′-deoxyuridine incorporation, cell counting, and wound hearing experiments were performed to assess NSCLC cell migration and proliferation. Hippocampus experiment was used to detect cellular metabolism. Mouse tumor xenograft model was constructed to assess the hsa_circ_0000896 roles in NSCLC metastasis and progressions. The data revealed that M2-Exo treatment promoted NSCLC cell proliferation and migrations. Hsa_circ_0000896 in M2-Exos mediated NSCLC malignant progression, which was ameliorated by downregulation of hsa_circ_0000896 expression. Both SLC2A3 and miR-503-5p were identified as hsa_circ_0000896 downstream targets. SLC2A3 overexpression or miR-503-5p suppression can reverse hsa_circ_0000896 silence inhibit effects to NSCLC malignant progression. The hippocampus experiment confirmed that downregulation of hsa_circ_0000896 inhibited aerobic glycolysis by regulating miR-503-5p/SLC2A3. A549-DDP were used to construct a subcutaneous tumor model, outcomes of which showed that downregulation of hsa_circ_0000896 increased NSCLC chemosensitivity. Together, our results revealed that exosomes from TAMs promoted glycolysis and malignant progression of NSCLC by delivering hsa_circ_0000896. And hsa_circ_0000896 can promote glycolysis by regulation miR-503-5p/SLC2A3.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.